| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
REGN
Regeneron
|
Oct 01, 2026 | BUY |
Strong Buy
+7.7% avg upside
59 analysts
|
$930.00
26.59% Upside
|
· | · |
|
VRTX
Vertex Pharmaceuticals
|
Sep 23, 2026 | BUY |
Strong Buy
-13.0% avg upside
62 analysts
|
$640.00
26.37% Upside
|
-1.9% | · |
|
LLY
Eli Lilly & Co
|
Sep 22, 2026 | BUY |
Strong Buy
-6.9% avg upside
49 analysts
|
$1440.00
25.29% Upside
|
-1.1% | · |
|
ALKS
Alkermes
|
Sep 22, 2026 | BUY |
Strong Buy
+7.4% avg upside
34 analysts
|
$83.00
104.78% Upside
|
-6.4% | · |
|
GB:0QW0
arGEN X
|
Sep 15, 2026 | BUY |
Strong Buy
-25.5% avg upside
25 analysts
|
— | · | · |
|
BNTX
BioNTech SE
|
Sep 15, 2026 | BUY |
Strong Buy
+38.4% avg upside
26 analysts
|
$138.00
42.46% Upside
|
+1.9% | · |
|
SYRE
Spyre Therapeutics
|
Sep 09, 2026 | BUY |
Strong Buy
+5.1% avg upside
24 analysts
|
$126.00
40.12% Upside
|
+2.4% | · |
|
LTGO
Latigo Biotherapeutics, Inc.
|
Sep 01, 2026 | BUY |
Strong Buy
+245.7% avg upside
3 analysts
|
$50.00
199.62% Upside
|
-23.0% | · |
|
BMRN
BioMarin Pharmaceutical
|
Aug 31, 2026 | BUY |
Strong Buy
+64.1% avg upside
52 analysts
|
$105.00
79.61% Upside
|
-8.7% | · |
|
DMRA
Damora Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
+48.0% avg upside
20 analysts
|
$50.00
147.15% Upside
|
-31.9% | · |
|
JBIO
Jade Biosciences
|
Aug 11, 2026 | BUY |
Strong Buy
+320.3% avg upside
17 analysts
|
$48.00
248.63% Upside
|
-35.5% | · |
|
PFE
Pfizer
|
Aug 05, 2026 | BUY |
Buy
+19.8% avg upside
45 analysts
|
$34.00
20.99% Upside
|
+9.4% | · |
|
NBIX
Neurocrine
|
Jul 30, 2026 | BUY |
Strong Buy
+32.1% avg upside
37 analysts
|
$200.00
42.06% Upside
|
-24.1% | · |
|
IONS
Ionis Pharmaceuticals
|
Jul 15, 2026 | BUY |
Buy
+71.3% avg upside
43 analysts
|
$90.00
104.45% Upside
|
-19.6% | · |
|
GILD
Gilead Sciences
|
May 22, 2026 | BUY |
Strong Buy
-19.4% avg upside
66 analysts
|
$180.00
22.03% Upside
|
+11.1% | · |
|
CCCC
C4 Therapeutics
|
Apr 30, 2026 | BUY |
Strong Buy
+449.6% avg upside
19 analysts
|
$14.00
345.84% Upside
|
+5.3% | · |
|
AMGN
Amgen
|
Mar 10, 2026 | HOLD |
Buy
-20.8% avg upside
57 analysts
|
$350.00
14.11% Downside
|
+8.8% | · |
|
ARGX
Argenx Se
|
Feb 19, 2026 | BUY |
Strong Buy
-12.1% avg upside
48 analysts
|
$1008.00
7.72% Upside
|
+13.8% | · |
|
EXEL
Exelixis
|
Dec 11, 2025 | BUY |
Buy
-27.0% avg upside
34 analysts
|
$46.00
20.59% Downside
|
+40.0% | · |
|
CBIO
Crescent Biopharma
|
Dec 05, 2025 | BUY |
Strong Buy
+55.7% avg upside
17 analysts
|
$35.00
145.34% Upside
|
+7.0% | · |
|
ZYME
Zymeworks
|
Nov 17, 2025 | BUY |
Strong Buy
+28.7% avg upside
26 analysts
|
$42.00
61.72% Upside
|
+10.8% | · |
|
ENTA
Enanta Pharmaceuticals
|
Oct 01, 2025 | BUY |
Buy
+155.2% avg upside
17 analysts
|
$20.00
55.80% Upside
|
+24.2% | · |
|
CYTK
Cytokinetics
|
Sep 03, 2025 | BUY |
Strong Buy
+38.4% avg upside
36 analysts
|
$80.00
21.86% Upside
|
+47.9% | · |
|
MDGL
Madrigal Pharmaceuticals
|
Aug 12, 2025 | BUY |
Strong Buy
+3.1% avg upside
34 analysts
|
$502.00
0.56% Upside
|
+49.4% | · |
|
MRK
Merck & Company
|
Jun 18, 2025 | BUY |
Strong Buy
-1.2% avg upside
43 analysts
|
$138.00
4.05% Downside
|
+48.4% | · |
|
ARVN
Arvinas Holding Company
|
May 02, 2025 | HOLD |
Strong Buy
+280.5% avg upside
28 analysts
|
$10.00
34.52% Upside
|
+36.1% | · |
|
BMY
Bristol-Myers Squibb
|
Apr 23, 2025 | BUY |
Buy
+0.2% avg upside
42 analysts
|
$68.00
10.66% Upside
|
+27.7% | · |
|
JAZZ
Jazz Pharmaceuticals
|
Apr 01, 2025 | BUY |
Strong Buy
+6.8% avg upside
36 analysts
|
$183.00
21.45% Downside
|
+50.6% | · |
|
ZNTL
Zentalis Pharmaceuticals
|
Jan 29, 2025 | HOLD |
Buy
+420.9% avg upside
20 analysts
|
$2.50
4.09% Downside
|
+32.8% | · |
|
RLAY
Relay Therapeutics
|
Dec 11, 2024 | BUY |
Strong Buy
+19.7% avg upside
21 analysts
|
$17.00
8.04% Downside
|
+56.4% | · |
|
ACRV
Acrivon Therapeutics, Inc.
|
Dec 12, 2022 | BUY |
Strong Buy
+605.7% avg upside
13 analysts
|
$17.00
745.84% Upside
|
-60.1% | · |
|
VTRS
Viatris
|
Feb 26, 2021 | HOLD |
Buy
+34.0% avg upside
22 analysts
|
— | +1.0% | · |
|
TSE:BHC
Bausch Health Companies
|
Jan 29, 2020 | HOLD |
Buy
+624.1% avg upside
29 analysts
|
— | -15.2% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.